Navigation Links
Modern targeted drug plus old malaria pill serve a 1-2 punch in advanced cancer patients
Date:4/5/2011

ORLANDO -- Researchers at the University of Pennsylvania School of Medicine may have found a way to turn an adaptive cellular response into a liability for cancer cells. When normal cells are starved for food, they chew up existing proteins and membranes to stay alive. Cancer cells have corrupted that process, called autophagy, using it to survive when they run out of nutrients and to evade death after damage from chemotherapy and other sources. When the Penn investigators treated a group of patients with several different types of advanced cancers with temsirolimus, a molecularly targeted cancer drug that blocks nutrient uptake, plus hydroxychloroquine, an anti-malarial drug that inhibits autophagy, they saw that tumors stopped growing in two-thirds of the patients.

Amaravadi's team will present the data at the American Association for Cancer Research 102nd Annual Meeting 2011 in Orlando on Tuesday, April 5. (Abstract #4500)

"The results are very encouraging -- striking, even" says senior author Ravi Amaravadi, MD, an assistant professor of Medicine at Penn's Abramson Cancer Center. "Temsirolimus by itself has little effect in this patient population. Tumors laugh at it, with response percentages of just zero to 5 percent. But by combining it with hydroxychloroquine, we found that 14 out of 21 patients had stable disease after treatment, including five out of six melanoma patients."

In addition to melanoma, patients involved in the study also had colorectal, head and neck, breast, gastro-esophageal, prostate, pancreatic, lung and adrenal cancers. Not only did patients show substantial rates of disease stabilization with the treatment combination, but the researchers report that side effects observed were relatively limited; most commonly mouth sores, weight loss, nausea, and fatigue. Two patients developed infections when the large tumors they had at the start of the trial caved in on themselves as treatment killed off the internal cancer cells, but both patients responded to antibiotics and were able to remain on the study regimen.

Amaravadi's group was able to see evidence of autophagy inhibition in peripheral blood cells in patients treated with the combination. And the inhibition increased with increasing doses of hydroxychloroquine, suggesting that the drug is working as they hypothesized it would.

More serious side effects, including low blood cell counts, in a previous phase I trial that combined hydroxychloroquine with chemotherapy and radiation. "That was unexpected and shows that hydroxychloroquine is an experimental drug, even though it has been approved for other treatments for many years," he says. "We didn't see that problem in this trial, so our findings show that what you combine it with is critical and some combinations will be less tolerable."

The researchers note that the relatively limited side effect profile of the novel temsirolimus-hydroxychloroquine combination suggests researchers may be able to layer other therapies on top of it, making the combination an even more powerful treatment.

Given the large proportion of melanoma patients who benefited from this combination in the initial cohort of patients, the investigators are currently enrolling an additional 12 patients in an expansion cohort at the 1200 mg dose of hydroxychloroquine. They are also hopeful that the drug combination will also be useful in patients with head and neck and breast cancers.


'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Related medicine news :

1. Study shows that modern surgery for scoliosis has good long-term outcomes
2. Learning from old bones to treat modern back pain
3. Famed neurosurgeons century-old notes reveal modern style admission of medical error
4. Sows ears and silk purses: Packing more flavor into modern pork
5. The brains journey from early Internet to modern-day fiber optics -- all in 1 lifetime
6. Action of modern drug demonstrates how 2 ancient human systems interact
7. The New 2010 Modernized Medicare Supplement Plans: Positive Changes in the Midst of Health Care Reform
8. Denver Plastic Surgeon Deploys Sophisticated Lasers in Modern Beauty, Anti-aging Treatments
9. Modern medicine conquers witchcraft
10. Bloomberg School of Public Health awarded $15 million for laboratory renovation and modernization
11. iVillage Prescribes New Health Site for the Modern Woman
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... ... September 20, 2017 , ... “The Financial Favor of God; Second Edition”: a ... Second Edition” is the creation of published author, Brooks Rathell. , “We typically hear ... to you about the financial favor of God. Not only does it exist, but ...
(Date:9/19/2017)... , ... September 19, 2017 , ... Only a few ... honorees include Brevard’s own Ross A. Clevens, MD, FACS . The founder and ... Facial Plastic and Reconstructive Surgeon who trained at Yale, Harvard and the University of ...
(Date:9/19/2017)... ... September 19, 2017 , ... ... for the President’s Malaria Initiative (PMI) Africa Indoor Residual Spraying (AIRS) Project ... Award. , The Innovation to Action Award, a USAID Catalyst Award, recognizes ...
(Date:9/19/2017)... , ... September 19, 2017 , ... ... addition of Canyon Ranch to its recently formed Corporate Roundtable, a ... sustainable healthcare system and a sustainable world. , Canyon Ranch is a unique ...
(Date:9/19/2017)... FORT LEE, N.J. (PRWEB) , ... September 19, 2017 , ... ... of the Subperiosteal Implant: Volume II ” (published by Xlibris on July of 2014). ... and reviews conventional and new methodological approaches that benefit people who have lost ...
Breaking Medicine News(10 mins):
(Date:9/9/2017)... Sept. 8, 2017 Dealmed Medical Supplies, ... of medical equipment, supplies, drugs, vaccines, and specialty medical ... into an agreement to acquire Vantage Medical Supplies, a ... Holtsville, New York . ... new and emerging medical practices, will operate under the ...
(Date:9/7/2017)... , Sept. 7, 2017  Eli Lilly ... announced actions to streamline operations to more efficiently ... improve its cost structure. Global workforce reductions, including ... are expected to impact approximately 3,500 positions. ... company expects annualized savings of approximately $500 million ...
(Date:9/7/2017)... Texas , Sept. 7, 2017 ... science focused on fulfilling the promise of precision ... further validate the benefits of its molecular profiling ... study utilized comprehensive genomic profiling plus (CGP+) with ... individual patient,s tumor on a molecular level, leading ...
Breaking Medicine Technology: